Drug Profile
PT 20
Alternative Names: Modified ferric oxide adipate - Shield therapeutics; PT-20Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Medical Research Council
- Developer Medical Research Council; Phosphate Therapeutics
- Class Ferric compounds; Hyperphosphataemia therapies; Small molecules
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Hyperphosphataemia in United Kingdom (PO)
- 27 Sep 2016 Phase-II development is ongoing in USA
- 20 Sep 2016 PT 20 will be available for licensing as from 01 Jan 2017. http://www.shieldtherapeutics.com/investors/